UNASSIGNED: Our analysis included RCTs that evaluated adjunctive tACS\' effectiveness, tolerability, and safety in schizophrenia patients. Three independent authors extracted data and synthesized it using RevMan 5.3 software.
UNASSIGNED: Three RCTs involving 76 patients with schizophrenia were encompassed in the analysis, with 40 participants receiving active tACS and 36 receiving sham tACS. Our study revealed a significant superiority of active tACS over sham tACS in improving total psychopathology (standardized mean difference [SMD] = -0.61, 95% confidence interval [CI]: -1.12, -0.10; I2 = 16%, p = 0.02) and negative psychopathology (SMD = -0.65, 95% CI: -1.11, -0.18; I2 = 0%, p = 0.007) in schizophrenia. The two groups, however, showed no significant differences in positive psychopathology, general psychopathology, or auditory hallucinations (all p > 0.05). Two RCTs examined the neurocognitive effects of tACS, yielding varied findings. Both groups demonstrated similar rates of discontinuation due to any reason and adverse events (all p > 0.05).
UNASSIGNED: Adjunctive tACS is promising as a viable approach for mitigating total and negative psychopathology in individuals diagnosed with schizophrenia. However, to gain a more comprehensive understanding of tACS\'s therapeutic effects in schizophrenia, it is imperative to conduct extensive, meticulously planned, and well-documented RCTs.
■我们的分析包括评估辅助tACS有效性的随机对照试验,耐受性,以及精神分裂症患者的安全性。三个独立作者提取数据并使用RevMan5.3软件进行合成。
■分析了涉及76名精神分裂症患者的三项随机对照试验,40名参与者接受主动tACS,36名参与者接受假tACS。我们的研究表明,在改善总精神病理学方面,主动tACS优于假tACS(标准化平均差[SMD]=-0.61,95%置信区间[CI]:-1.12,-0.10;I2=16%,p=0.02)和阴性精神病理学(SMD=-0.65,95%CI:-1.11,-0.18;I2=0%,p=0.007)在精神分裂症中。两组,然而,在积极的精神病理学上没有显着差异,一般精神病理学,或幻听(所有p>0.05)。两个RCT检查了tACS的神经认知效应,产生不同的发现。两组由于任何原因和不良事件而停药的发生率相似(均p>0.05)。
■辅助tACS有望成为缓解精神分裂症患者总体和消极精神病理学的可行方法。然而,为了更全面地了解tACS在精神分裂症中的治疗效果,必须广泛开展,精心策划,和有据可查的RCT。